Apotea AB (publ) (STO:APOTEA)

Sweden · Delayed Price · Currency is SEK

65.40

-1.70 (-2.53%)

At close: Apr 27, 2026

-14.84% (1Y)

Market Cap	6.81B
Revenue (ttm)	7.21B
Net Income (ttm)	228.70M
Shares Out	104.07M
EPS (ttm)	2.20
PE Ratio	29.76
Forward PE	26.27
Dividend	0.60 (0.92%)
Ex-Dividend Date	n/a

Volume	190,060
Average Volume	479,908
Open	67.15
Previous Close	67.10
Day's Range	65.35 - 67.60
52-Week Range	54.42 - 122.00
Beta	n/a
RSI	56.55
Earnings Date	Apr 17, 2026

About Apotea AB

Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food and drink, mouth and teeth, premium, trip, sex and lust, stop smoking, makeup, sun protection, wounds and injuries, sleep and sleep problems, training, weigh... [Read more]

Industry Pharmaceutical Retailers

Sector Healthcare

Founded 2011

Employees 727

Stock Exchange Nasdaq Stockholm

Ticker Symbol APOTEA

Full Company Profile

Financial Performance

In 2025, Apotea AB's revenue was 7.21 billion, an increase of 10.06% compared to the previous year's 6.55 billion. Earnings were 228.70 million, an increase of 6.42%.

Financial Statements

News

Apotea AB Earnings Call Transcript: Q4 2025

Q4 saw 7% revenue growth but weaker profitability due to campaign intensity and Varberg ramp-up costs. Full-year growth was strong at 10.1%, with major investments completed and new growth initiatives underway, including expansion into Norway.

2 months ago - Transcripts

Apotea AB Earnings Call Transcript: Q3 2025

Q3 saw 8.9% revenue growth, a 5% EBIT margin, and strong Rx sales, supported by the successful Varberg warehouse launch and efficiency gains. Net cash reached SEK 98 million, with a focus now shifting to external growth and leveraging new capacity.

6 months ago - Transcripts

Apotea AB Earnings Call Transcript: Q2 2025

Revenue grew 9.9% to SEK 1.826 billion, driven by strong RX demand and stable gross margins. Profitability improved, with an adjusted EBIT margin of 5.4%, and the Varberg facility is set to boost future efficiency. Net cash position remains strong.

10 months ago - Transcripts

Apotea AB Earnings Call Transcript: Q1 2025

Q1 saw 15.2% revenue growth and improved EBIT margin to 5.3%, driven by stable demand and efficiency gains. Preparations for the Varberg fulfillment center are on track, expected to boost capacity by 50%. Guidance remains cautious due to upcoming cost increases and market uncertainties.

1 year ago - Transcripts

Apotea AB Earnings Call Transcript: Q4 2024

Q4 saw 15.8% revenue growth to SEK 1.7 billion, stable margins, and improved profitability, driven by strong Rx sales and automation. Major investments in fulfillment and AI, plus a successful IPO, position the company for further growth and efficiency gains.

1 year ago - Transcripts